This article has been disseminated on behalf of  Silvercorp Metals Inc. (NYSE-A/TSX: SVM) and may include paid advertising.

• Canada-based Silvercorp Metals produces silver, gold, lead, zinc and other metals with primary mining operations in China and advancing growth projects in Ecuador
• Q2 Fiscal 2026 revenue rose 23% YOY to approximately $83.3 million
• Q2 silver equivalent (silver and gold) production of 1.84 million ounces, a 5% increase YOY
• Construction continues at the El Domo project in Ecuador, while Silvercorp’s investment in New Pacific Metals provides exposure to two advanced silver projects in Bolivia

Precious metals producer Silvercorp Metals (NYSE American/TSX: SVM) continues to build momentum in its quest to generate sustainable economic, social and environmental value for all its stakeholders at a level that is beginning to span the globe. 

The Canadian mining company has an 18-year operating track record and recently reported year-over-year growth in its revenues, thanks to strong metal prices and increasing silver, gold and lead production at its mines in China. 

Silvercorp’s Oct. 15 news release notes that revenues rose approximately 23% over the same quarter a year previous, ending its recently completed Q2 2026 with approximately $83.3 million in sales. Its silver production at the Ying Mining District rose 1% to about 1,529 thousand ounces, gold rose 76% to 2,085 ounces, and lead rose 8% to 12,928 thousand pounds (https://ibn.fm/l1ZBy).

Silvercorp expects to publish all its unaudited interim financial results for the second quarter on Nov. 6. 

“Being in China, we’re close to the source of supply for a lot of the inputs that go into mining,” said Silvercorp President Lon Shaver earlier this month during an interview with Natural Resource Stocks, speaking of the company’s operating advantages (https://ibn.fm/tAy58). “So we don’t have to carry a lot of working capital. We can get, on a pretty competitive basis, inputs and supplies,” he added. “And a real testament to that is we expanded in 2024 our milling facility and bumped it up quite significantly from 2,500 tons per day of capacity to 4,000 tons per day.” 

While the Ying site, comprising seven mines (plus an additional satellite site) and two milling facilities, is “the real economic driver” for the company, Shaver noted that Silvercorp has an additional producing mine in the southern part of the country as well as an additional gold resource “on care and maintenance” in China, plus two new sites being developed for production half a world away in Ecuador that were part of a more recent acquisition. 

“At the other end, on incubation, we have a meaningful investment in New Pacific, which is another public company advancing two very attractive silver projects in Bolivia. And so that is somethings we’ve been helping to support and nurture as they’ve gone through technical studies and now are into the permitting phase,” Shaver said. “We’re pretty open-minded to look at what we think could be value-creating, mine-building opportunities for us.”

Production levels at the Ying district and the GC Mine in China reflect interruptions due to a temporary closure at Ying and severe typhoon weather conditions at GC. During the Q2 fiscal period, Ying completed 64,330 meters of drilling and 12,638 meters of exploration tunneling, while GC completed 13,176 meters of drilling and 1,799 meters of exploration tunneling.

The 481-bed construction camp at the Ecuadorian El Domo mine was set to be fully operational in October and construction there has advanced with a 249% increase in earthen material moved over the previous quarter.

For more information, visit the company’s website at https://silvercorpmetals.com/welcome.

Third-Party Disclaimer:

The IBN website may contain third-party content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer.

• Beeline Holdings recently announced that it locked 21 loans worth nearly $8 million on the same day the Federal Reserve announced its second consecutive 25-basis-point rate cut.
• The company also announced the launching of BeelineEquity, a blockchain-based fractional equity platform that gives homeowners debt-free access to their property value.
• Management will cover these and other accomplishments when it hosts a Q3 2025 stakeholder update call on November 10, led by CEO Nick Liuzza and CFO Chris Moe.

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform that redefines the path to homeownership, reported record performance at the end of October 2025, as the Federal Reserve announced its second consecutive quarter-point rate cut. On October 29, the company locked 21 loans with a total value of just under $8 million, setting a new high in its core revenue indicator, a measure that typically translates into realized revenue within 30 to 45 days (https://ibn.fm/YRqFs).

The results signal that Beeline, which announced in September that it is debt-free, is now gaining traction after enduring the most difficult housing market in decades. The company expects to reach cash-flow positivity in early 2026, supported by a scalable AI-driven lending infrastructure and a growing base of non-traditional borrowers.

“Our key performance indicators are quickly improving which we knew would happen as the market normalized,” said Nick Liuzza, co-founder and CEO of Beeline. “We fought through the worst real estate market in 30 years to put Beeline in a position to capitalize when conditions normalized and here we are as the industry headwinds are turning into tailwinds. While it was a good day, it’s only the beginning of a strong run.”

Liuzza also added: “Beeline is serving two large demographics:  For millennials as a mortgage platform designed for the Gig economy, and for boomers as an equity product in areas where they hold $10T of equity.”

Beeline’s record day coincides with what many analysts view as the start of a more favorable lending cycle. The Fed’s back-to-back rate cuts have already led to modest drops in mortgage rates, with refinancing activity and purchase inquiries beginning to rise.

Beeline’s business model was designed for moments like this. Its AI-enabled proprietary platform can scale loan processing volumes rapidly while maintaining operational efficiency. By automating much of the underwriting and documentation process, Beeline can approve loans within minutes and close them in as few as 14 to 21 days, less than half the industry average. The platform’s design also caters to a changing borrower demographic. According to National Mortgage Professional, only 26.1% of Gen Z and 54.9% of Millennials owned homes in 2024, reflecting limited access to affordable mortgages (https://ibn.fm/M3J7F). Beeline’s tools, including its AI decision engine and chatbot “Bob,” aim to close that gap, giving buyers near-instant certainty about mortgage eligibility.

In addition, a significant share of Beeline’s clients are real estate investors, particularly among younger buyers seeking property investment opportunities as an entry point into wealth building.

The record loan announcement came shortly after Beeline declared a milestone that expands its reach beyond traditional lending. Through its subsidiary Beeline Loans, Inc., the company completed its first round of blockchain-recorded equity transactions under its new BeelineEquity product (https://ibn.fm/Owvx8).

BeelineEquity offers homeowners a debt-free way to access liquidity by selling a fractional share of their home’s equity instead of taking out a loan. The structure eliminates monthly payments and interest, with repayment triggered only upon the sale or transfer of the property. Each transaction is securely recorded on the blockchain, ensuring transparency and immutability.

The company finalized five equity transactions during the pilot phase and plans to close an additional 30 by the end of 2025, citing strong homeowner demand for alternatives to traditional refinancing and home equity loans.

“Homeowners shouldn’t have to borrow against themselves just to access the value they’ve already built,” said Liuzza. “By putting home equity on blockchain rails, we’re creating a smarter, more transparent financial alternative — one that’s free from interest rate swings and credit friction.”

Beeline estimates that its new product addresses a vast, underutilized market: roughly $15 trillion in inaccessible U.S. home equity, much of it concentrated among Baby Boomers. Capturing even 10 basis points of that market could generate over $500 million in revenue, according to company projections.

Co-founder and COO Jess Kennedy said the launch of BeelineEquity gives the company two complementary revenue streams: “We’re offering more non-QM products than many top lenders and large banks to complement our conventional business and with the launch of our unique equity product, we now have two powerful revenue streams gaining momentum at the same time — a rare and exciting opportunity.”

Beeline’s recent performance and product innovation come less than a year after completing its October 2024 merger with Eastside Distilling, a move that redefined the company as a next-generation fintech mortgage originator. Since then, Beeline has built a vertically integrated lending and title platform that reduces friction, shortens closing timelines, and improves borrower experience. The company’s proprietary Hive production engine and automation stack enable efficient processing of multiple product types, from conventional loans to non-qualified mortgage (non-QM) products and investment property loans.

Following its record October performance, Beeline also confirmed plans to host its Q3 2025 stakeholder update call on November 10 at 5:00 PM ET (https://ibn.fm/rG2iV). CEO Nick Liuzza and CFO Chris Moe will discuss quarterly financials and provide updates on growth initiatives, lending performance, and the progress of BeelineEquity.

For more information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• Beeline Holdings, modernizing mortgage lending by aligning technology with the digital expectations of younger generations, targeting real estate investors as well as home buyers, is filling a gap that many other industry players don’t, and is now on track to go cash positive by Q1 2026
• While appearing on the latest episode of The TechMediaWire Podcast, Beeline’s CEO and Co-Founder, Nick Liuzza, talked about the company’s developments, mentioning the leadership’s confidence in its products, as evidenced by their monetary investment in the company
• Liuzza noted that Beeline has invested millions in the development of its product, an investment that led to a $7 million debt at the beginning of 2025, and how clearing off all its debts as of September 5, the company is on track to go cash flow positive

Beeline Holdings (NASDAQ: BLNE), a technology-forward mortgage and title platform that leverages AI, automation, and intuitive user experiences to simplify home financing, hit a significant milestone on September 5, 2025, having paid off all its debts, staying on track to go cash flow positive by Q1, 2026. While appearing on the latest episode of The TechMediaWire Podcast, Beeline Holdings’ CEO and Co-Founder, Nick Liuzza, acknowledged important progress the company has made and pointed out the investments and commitments that have led the company to its current position (https://ibn.fm/DVLlt).

Most notably, Liuzza noted the leadership’s confidence in its product, as evidenced by their monetary investment in the company. “We believe in what we do, and we put our money where our mouth is. I have $16 million invested in the company. Our COO has several hundred thousand dollars in the company. Our CFO is vested. Our management and product teams in Australia are vested,” he noted. “We believe in what we’re doing, and as a result of that, we’ve written checks to buy shares and grow the appreciation – and recognize the appreciation – as shareholders,” he added (https://ibn.fm/DVLlt).

Beeline Holdings has positioned itself as a next-generation fintech mortgage originator. Its primary vision is centered on digitizing the mortgage industry with AI tools, all while expanding its SaaS product suite. The efforts are shaped to make home loans effortless by providing users with instant access to rate quotes, approvals, and document uploads, all online and available 24/7. It takes into account the current challenges in the market, mainly influenced by products that were created decades ago.

The current mortgage products have remained largely unchanged since the 1970s, having been shaped and influenced by key events and key Acts, including, but not limited to, the founding of Freddie Mac, the 1975 Mortgage Disclosure Act, the introduction of adjustable-rate mortgages in the 1980s, and even the housing crisis of 2008 (https://ibn.fm/hkkvB). However, with the current growing population of millennials and Gen Z markets, an entire generation has grown up differently than when the current products were created, and they don’t work for them anymore, an aspect that Liuzza acknowledges.

“There are 75 million millennials out there…they grew up with smartphones. There’s 25 million Gen Z behind them,” noted Liuzza. “Almost a third of the population grew up differently than when the mortgage industry created their products back in the day. Enter Beeline, which has designed a brand and product to address this market with faster, better, more credible information, supporting a wider variety of products…that is consistent, accurate, and available 24/7, 365,” he added.

This focus has seen the company invest millions into the development of its product. Its biggest spend, according to Liuzza, has been on developing and creating to execute on its vision, an investment that led to the company entering 2025 with $7 million in debt. However, as of September 5, the company has since cleared off all its debts and is on track to go cashflow positive by the beginning of 2026.

“We entered 2025 with $7 million in debt. Our goal was to be debt-free by the end of 2025. We actually achieved that on September 5. We’re on our way to cash flow positive for Q1 2026,” noted Liuzza. “We have the tailwinds, and, now that we’re on track to go cashflow positive, we’ll look to fund that continued development through our earnings,” he added (https://ibn.fm/DVLlt).

As it works to modernize mortgage lending by aligning technology with the digital expectations of younger generations, including real estate investors as well as home buyers, Beeline Holdings is focused on having the customer experience at the heart of everything they do. By understanding pain points and fully appreciating the issues involved, they see themselves as building a product that resonates with customers and fills a gap that most companies in its space have failed to address for years, representing a tremendous opportunity for growth.

To listen to the full episode, please visit: https://ibn.fm/KV2XX

For company information, visit the company’s website at www.MakeABeeline.com.

NOTE TO INVESTORS: The latest news and updates relating to BLNE are available in the company’s newsroom at https://ibn.fm/BLNE

• The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix.
• The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing.
• SNGX has outlined a timeline of catalysts extending through the end of 2026.

Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company focused on rare diseases and biodefense programs, continues to fortify its financial position as it advances toward a series of pivotal and potentially transformational milestones. Following a series of strategic capital initiatives, including a $7.5 million public offering (https://ibn.fm/QKXcv), the company now reports a cash runway extending through the end of 2026, providing the resources needed to reach key clinical and regulatory inflection points across its diversified pipeline.

The financing initiatives underscore a disciplined approach to capital management at a critical stage for Soligenix, whose portfolio includes both late-stage therapeutics and vaccine candidates addressing high-unmet-need indications. With the recent financing in place, the company anticipates it will have sufficient capital to fund operations through multiple expected catalysts, including clinical updates, regulatory interactions and potential partnership opportunities. Soligenix noted that these moves were designed to reduce short-term funding pressure while preserving shareholder value amid ongoing progress in its core programs.

In the company’s announcement of the $7.5 million raise, Soligenix detailed that it issued approximately 5.56 million shares (or common-stock equivalents) and accompanying warrants at $1.35 per unit, generating gross proceeds of roughly $7.5 million before fees. The financing also involved amendments to prior warrants from 2023 and 2024, standardizing terms and improving future capital flexibility. The company’s leadership has emphasized that this strengthened balance sheet allows Soligenix to focus on execution rather than financing, ensuring operational continuity through expected value-creating milestones.

That stability is especially important given the potential embedded in Soligenix’s development pipeline. The company has outlined a timeline of catalysts extending through 2026 (https://ibn.fm/MtsAv). These include progress on its lead candidate HyBryte(TM) (synthetic hypericin) for cutaneous T-cell lymphoma (“CTCL”), SGX302 for psoriasis, SGX945 for Behçet’s disease, and SGX942 for oral mucositis in head and neck cancer. HyBryte, which has already achieved positive phase 3 results, remains the company’s anchor asset, with regulatory and commercialization preparations highlighted as near-term objectives.

Soligenix’s Public Health Solutions segment represents another key value stream. This division develops heat-stable vaccines and biodefense countermeasures using the company’s proprietary ThermoVax(R) platform. Its pipeline includes RiVax(R), a ricin toxin vaccine candidate that has been supported by multiple U.S. government contracts, as well as preclinical work on vaccine candidates for Ebola, Marburg and COVID–19. Collectively, these programs represent dual potential: near-term catalysts in rare-disease therapeutics and long-term value from government partnerships in biodefense.

With a financial runway now extending through 2026, Soligenix is strategically positioned to reach a convergence of data readouts, regulatory submissions and partnering opportunities without immediate dilution risk. For a development-stage biotech, this level of operational visibility provides a competitive advantage in both execution and investor confidence. The strengthened cash position also enables continued progress on clinical manufacturing, commercial readiness and global licensing initiatives, areas that typically require uninterrupted funding through regulatory transition phases.

Beyond the numbers, the company’s financial moves also suggest a broader maturation of its capital strategy. By aligning financing events with expected milestone timelines, Soligenix is signaling to the market that it intends to balance clinical progress with disciplined financial stewardship. This alignment between cash runway and value-driver cadence gives analysts and investors a clearer view of how upcoming catalysts could translate into enterprise growth.

Looking ahead, Soligenix’s combination of diversified programs, government-backed partnerships and an extended financial horizon presents a cohesive story of measured progress and high scientific potential. With cash resources projected to sustain operations through anticipated inflection points in 2026, the company is positioned to focus on what matters most: advancing late-stage assets toward market-ready outcomes.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://IBN.fm/SNGX

• A recent Simply Wall St analysis highlighted strong earnings growth and efficient profit reinvestment for SuperCom Ltd., with the company’s stock rising 22% over the past three months, reflecting renewed investor confidence.
• The company achieved 97% earnings growth year-on-year, far outpacing both industry and market averages, with five-year earnings growth standing at 45%, compared to 15% for the broader industry.
• SuperCom reinvests profits instead of paying dividends, channeling funds into its PureSecurity(TM) electronic monitoring platform and new market entries, allowing SuperCom’s return on equity (“ROE”) of 8.1% to align with industry norms while supporting consistent expansion.

SuperCom (NASDAQ: SPCB), a global provider of secured e-Government, IoT, and cybersecurity solutions, has drawn positive attention from analysts at Simply Wall St, which noted the company’s consistent earnings growth and improving fundamentals amid a period of stock strength (https://ibn.fm/Z862K).

Over the past quarter, SuperCom’s shares have climbed by more than 20%, supported by operational gains and continued adoption of its technology in the U.S. and Europe. The analysis points to the company’s ability to translate reinvested profits into sustained income growth, a trend that has differentiated it within its sector.

Simply Wall St’s evaluation focused on return on equity (“ROE”) as a measure of management efficiency. ROE indicates how effectively a company converts shareholder equity into profit. SuperCom’s ROE stood at 8.1% for the 12 months to June 2025, based on net income of approximately $3.0 million and shareholders’ equity of $37 million. While this figure is modest, it is broadly in line with the industry average of 9.7%.

The report further underlines that SuperCom’s performance has been notable for its rapid earnings expansion. Over the past five years, the company’s net income grew 45%, triple the 15% growth rate seen across comparable industry peers. Over the most recent fiscal year, earnings increased by 97%, compared to 4% growth across the broader industry and 9% across the general market. This combination of moderate capital efficiency and strong reinvestment discipline has contributed to the company’s improving market profile.

According to the Simply Wall St report, SuperCom’s growth trajectory has been supported by its decision to reinvest all profits into operations rather than distribute dividends. This reinvestment strategy has allowed the company to strengthen its core technologies, expand its geographic reach, and secure a series of new contracts, particularly in the electronic monitoring (“EM”) sector.

While earnings growth is often linked to high ROE, SuperCom’s performance suggests additional drivers at play, notably strategic execution, low payout ratios, and focused investment in scalable technologies. The report notes that management decisions appear to have amplified the effects of modest equity returns by prioritizing growth and cost discipline.

SuperCom’s earnings momentum is closely tied to its expansion in public safety and offender monitoring solutions. The company’s flagship PureSecurity(TM) suite integrates GPS, RFID, and cloud-based monitoring into a modular platform for various law enforcement and correctional applications.

• PureMonitor(TM), a cloud-based software hub for real-time supervision.
• PureOne(TM), a one-piece GPS bracelet for continuous tracking indoors and outdoors.
• PureCom(TM), a radio frequency (“RF”) base station for house arrest programs.
• PureTag(TM), a compact RF bracelet compatible with other PureSecurity components.
• PureTrack(TM), a smartphone-based GPS tracking system paired with the PureTag solution.
• PureShield(TM) (U.S.) and PureProtect(TM) (EU), mobile apps that improve the safety of domestic violence victims through proximity alerts.
• PureBeacon(TM), an RF device for indoor surveillance in environments where GPS signals are limited.
• PureReader(TM), used for monitoring inmate movements within detention centers.

These systems are designed to provide courts and agencies with actionable real-time data, improving supervision outcomes and enhancing public safety. The company’s technology is already in use across the U.S. and Europe, including multi-year contracts in Sweden, Germany, and Romania, where legacy systems are being replaced by SuperCom’s cloud-based infrastructure.

SuperCom’s business model aligns with a growing global focus on rehabilitation-based justice systems and digital transformation in public safety management. Research supports the effectiveness of electronic monitoring:

• In Argentina, EM reduced one-year recidivism by 48% (Di Tella & Schargrodsky, 2013) (https://ibn.fm/oszmo).
• In Australia, it lowered two-year reoffending rates by 28% (Williams & Weatherburn, 2020) (https://ibn.fm/LBai9).
• In France, EM reduced five-year recidivism by 10% (Henneguelle et al., 2016) (https://ibn.fm/zvZbb).

These findings underline the social and economic value of monitoring solutions — reducing incarceration costs while supporting rehabilitation.

SuperCom’s stock performance over recent months may also reflect renewed confidence in its U.S. operations, where the company continues to secure new contracts through its PureSecurity(TM) reseller network. In recent announcements, SuperCom reported multiple state-level wins, including deployments in Virginia, Kentucky, and Utah, as part of a broader North American growth strategy.

The Simply Wall St review highlights SuperCom’s earnings growth far exceeding industry norms, indicating efficient use of reinvested capital. The Simply Wall St coverage underscores improving fundamentals, a strong earnings record and disciplined reinvestment strategy. With continued focus on reinvesting earnings, while strengthening its presence in key markets, SuperCom is viewed as well-positioned to maintain its growth momentum.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at https://ibn.fm/SPCB

• Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte(TM) (synthetic hypericin) and related therapies.
• These changes are timely given the complexities of CTCL and the evolving therapeutic landscape.
• The company’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight.

Soligenix (NASDAQ: SNGX), a clinical-stage biotechnology company focused on rare diseases and public health solutions, has rejuvenated its U.S. Medical Advisory Board for cutaneous T-cell lymphoma (“CTCL”), placing fresh expertise and leadership at the center of its HyBryte(TM) development program (https://ibn.fm/ueKOC). This strategic move signals the company’s deepening commitment to advancing its pipeline agents in CTCL and aligning clinical strategy with evolving standards of care.

Soligenix revealed updates to its U.S. Medical Advisory Board for CTCL designed to support the clinical advancement of HyBryte (synthetic hypericin) and related therapies; specifically, the updates include the addition of new members and the retirement of prior advisors. The company noted that the updated board reflects growing scientific insight into CTCL treatment pathways and is intended to enhance the translational and clinical strategic guidance for HyBryte’s potential regulatory and commercial trajectory.

“We are pleased to be able to attract such esteemed and enthusiastic professionals to participate as members of our Medical Advisory Board,” said Soligenix president and CEO Christopher J. Schaber. “Many of the MAB members have experience treating patients with HyBryte and have been invaluable to the program. We are excited to continue to work with them to facilitate the advancement of HyBryte to commercialization worldwide.” According to the company, the newly configured advisory board will provide counsel on pivotal trial design, regulatory engagement and potential strategic partnerships in CTCL.

These changes are timely given the complexities of CTCL and the evolving therapeutic landscape. CTCL is a rare form of non-Hodgkin lymphoma that primarily affects the skin and is characterized by malignant T-cells residing in the skin for prolonged periods. The condition can progress from patches and plaques to tumors, and in advanced stages may involve lymph nodes or internal organs.

According to the Lymphoma Research Foundation, around 3,000 new cases of CTCL are diagnosed in the U.S. annually, and the disease remains incurable (https://ibn.fm/op83a). Treatment options include skin-directed therapies, systemic agents, biologics and recently approved targeted therapies, but unmet needs persist, especially for relapsed or refractory disease and in patients who progress despite available options. The highly heterogeneous nature of CTCL and its variable course make clinical development particularly challenging.

In that context, the role of a strong and relevant Medical Advisory Board becomes crucial. Soligenix’s decision to refresh its CTCL advisory team reflects a recognition that commercialization preparation in the CTCL space, evolving regulatory expectations and the need for robust trial designs demand expert insight. The updated advisory board is expected to advise on patient population definitions, endpoint selection, dose optimization, long-term follow-up strategies and potential label positioning. For HyBryte, which has already demonstrated positive results in its first Phase 3 clinical trial, having an advisory board closely aligned with specialist clinicians and thought leaders may accelerate registration pathways, refine patient-selection strategies and support market-access planning.

Moreover, the timing aligns with Soligenix’s broader pipeline strategy. The company has noted that HyBryte is a lead value driver, with its next expected inflection points including data read-out and regulatory engagement in the 2025–2026 timeframe (https://ibn.fm/84p9u). By updating its advisory board now, Soligenix is aligning its governance and clinical strategy ahead of those anticipated milestones, positioning itself for disciplined execution and clearer regulatory dialogue.

Experts in CTCL treatment emphasize the importance of strategic collaborations and advisory input in rare-disease trials. Given the low incidence of CTCL and diversity of disease presentation, engaging a board with recognized clinical experience in cutaneous lymphoma, dermatology-oncology interplay and regulatory mindset can enhance trial recruitment, endpoint relevance and payer discussions post approval. Soligenix’s updated board may also contribute insight into combinatorial strategies, development of biomarker-driven patient subgroups and incorporation of patient-reported outcomes, all of which are increasingly emphasized by regulatory authorities and payers in rare-disease drug development.

From an investor vantage point, this advisory board update signals that Soligenix is not only advancing its HyBryte therapy but also refining the infrastructure around it, an often underrated aspect of clinical-stage biotech execution. With an extended cash runway, thanks in part to a recent $7.5 million public offering (https://ibn.fm/QKXcv) and a refreshed advisory board guiding its CTCL strategy, the company looks to be better positioned as it moves forward.

The company’s update to its U.S. Medical Advisory Board for CTCL reflects strategic alignment with the complex and evolving CTCL therapeutic landscape. With HyBryte as a core value driver and a clinical development timetable that points into 2026, the company is actively preparing the frameworks, both scientific and regulatory, for advancement and potential commercialization. As CTCL remains an area of considerable unmet need, Soligenix’s refreshed advisory board may serve as a differentiator in successfully navigating that terrain.

For more information, visit www.Soligenix.com.

NOTE TO INVESTORS: The latest news and updates relating to SNGX are available in the company’s newsroom at https://IBN.fm/SNGX

• The company revealed the trial at the Australia Translational Breast Cancer Research Symposium (“ATBCR”)
• Sapu-003 is an injectable formulation of Everolimus (Afinitor(R)), which aims to offer higher bioavailability and better efficacy than oral versions of the drug
• The trial is conducted alongside partners like the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon

Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003.

The announcement occurred at the Australian Translational Breast Cancer Research Symposium (“ATBCR”).

Sapu-003 is the first IV Deciparticle(TM) formulation of Everolimus (Afinitor(R)), which is an mTOR inhibitor that’s widely used in oncology to treat various forms of cancer. While oral Everolimus (Afinitor(R)) is effective at treating breast cancer, neuroendocrine tumors, and renal cell carcinoma, broader use has been inhibited due to its low bioavailability and variable systemic exposure.

In contrast, Sapu-003 aims to offer much higher bioavailability, which will allow more of the drug to enter the patient’s system.

The Sapu-003 trial is being conducted in collaboration with the Southern Oncology Clinical Research Unit (“SOCRU”), Ingenū, and Medicilon. These partnerships ensure that the clinical trial is executed precisely, aligns with regulations compliance, and to manage and monitor all aspects of the trial for favorable outcome.

This trial (ACTRN12625001083482) is open to leading oncology centers for enrollment. The eligible participants include both adults with advanced HR+/HER2– breast cancer and those with other mTOR-sensitive tumors that have already tried other standard therapies.

When speaking about Sapu-003 and the trial, CEO of Sapu Nano, Dr. Vuong Trieu said that “Sapu-003 represents a significant advancement in the delivery of mTOR-targeted therapies,”. He also added that “Through the combined expertise of SOCRU, Ingenū, and Medicilon, we are positioned to accelerate development and bring this next-generation treatment option to patients with advanced cancers.” 

Oncotelic Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing therapeutics to help fight cancer and pediatric diseases with high unmet medical needs. Oncotelic leverages the portfolio of inventions by its CEO, Dr. Vuong Trieu, who has filed over 500 patent applications with 75 issued patents. The company also enhances its capabilities through strategic partnerships, licensing, and joint ventures — notably its 45% ownership of GMP Bio, led by Dr. Trieu, which is advancing complementary drug candidates that strengthen Oncotelic’s leadership in therapeutics.

For more information, visit the company’s website at www.Oncotelic.com.

NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC

The Blockchain Futurist Conference Florida 2025 is preparing to ignite Miami this November 5–6, delivering a high-energy, future-forward experience where Web3, crypto, and AI collide. Now just days away, the event has officially released its full agenda, offering a first look at the groundbreaking conversations, powerhouse speakers and cultural moments set to define this year’s show.

Hosted at DAER inside the iconic Hard Rock Guitar Resort, the 2025 Futurist Conference marks the event’s first-ever U.S. edition and promises an immersive two-day lineup built for builders, innovators, investors, creators and future-thinkers shaping digital economies.

From the moment doors open on Day 1, attendees will move through a packed schedule across the Main Stage, Rooftop Stage and Argentum AI Stage, each programmed to spark ideas, expand networks and accelerate the next wave of industry breakthroughs.

Expect big-picture keynotes on AI regulation, tokenized economies, and global crypto adoption, followed by high-impact panels diving into real-world implementation: DeFi, stablecoins, on-chain identity, decentralized governance, and scaling crypto infrastructure. And yes, signature rooftop energy returns, delivering Miami vibes, skyline views and open-air conversations that fuel the best deal-flow and discoveries.

The second day pushes deeper into execution and strategy. Venture insights, startup showcases, and hands-on technical explorations give founders, developers and investors real pathways to build and deploy.

The Argentum AI Stage, anchored by the fifth-annual AI Futurist program, shines a spotlight on the intersection of AI and Web3, exploring decentralized AI systems, hybrid compute, next-gen token models and the future of intelligent autonomous networks.

Agenda Highlights

With the release of the official schedule, attendees can now explore cornerstone sessions including:

• The Future of Cross-Border Payments: How Blockchain and Digital Currencies Are Transforming Global Trade & Finance
• Stablecoins & Market Liquidity: Safety Net or Volatility Driver?
• DAOs & the Future of Governance: Rethinking Decision-Making in a Decentralized Era
• Beyond the Hype: NFTs and the Next Evolution of Digital Ownership

Explore the full schedule here: https://www.futuristconference.com/schedule

Combined with fireside chats, live demos, AI workshops and brand activations across two expo floors and 30+ VIP cabanas, Futurist Miami is engineered for discovery, access and acceleration.

True to the Futurist identity, this year’s programming blends cutting-edge industry content with cultural pulse and star presence. With celebrity-led discussions, creator-driven projects, and emerging tech talent on stage, the conference continues its role as a cultural bridge, where mainstream meets metaverse and influence meets innovation.

The Future Arrives in Miami

As the Miami tech scene continues to surge, Futurist 2025 lands at the perfect moment: when Web3 and AI are transitioning from theory to global impact, and the builders leading that shift are ready to share what comes next.

Whether you’re scaling a protocol, launching a startup, investing in the next wave or simply ready to learn from the leaders shaping tomorrow’s digital world, the only place to be this November is Blockchain Futurist Conference Florida 2025.

Bring your questions. Bring your curiosity. Bring your ambition. The future isn’t waiting, it’s being built at Blockchain Futurist.

For more information, visit www.FuturistConference.com.

This article has been disseminated on behalf of Trilogy Metals and may include a paid advertisement.

• Trilogy Metals CEO Tony Giardini discussed the Ambler Road, also known as the Ambler Access Project, that links the Dalton Highway to the Ambler Mining District.
• Interview touched on the granting of the road permits, what makes this part of Alaska so special, and the timeline of the work.
• Giardini also commented on the federal equity stake in Trilogy, upcoming key milestones for the company, and his thoughts on the most important metals for the economy and national security.

Tony Giardini, the CEO of Trilogy Metals (NYSE American: TMQ) (TSX: TMQ), a mineral exploration and development company, recently sat down for a chat about the Ambler Road with Rick Van Nieuwenhuyse, Chair of Valhalla Metals. 

The Ambler Road is a 211-mile industrial-use-only road connecting Alaska’s Dalton Highway to the Ambler Mining District. The road is a key piece of infrastructure that enables the exploration and development of the Ambler Mining District.

The conversation began with both executives talking about the history of the Ambler area and the efforts to secure road access. It then moved to the recent news of the federal government’s decision under Section 1106 of the Alaska National Interest Lands Conservation Act (“ANILCA”), which grants the permits for the Ambler Road.

This move by the U.S. administration unlocks one of the richest mineral districts in the country, which is home to the Arctic and Bornite deposits. President Trump also directed all relevant agencies to promptly grant and finalize all permits needed to ensure the area may be accessed for economic, mining, industrial, and commercial purposes.

In regards to the Presidential approval, Giardini called it more than a permit and said it’s really a legislatively backed pathway to unlock the district. Giardini continued to speak on how this area of Alaska is known for exceptional metal grades and the diversity of the different metals there, such as copper, zinc, cobalt, and precious metals.

Later in the chat, Giardini was asked about the Department of War’s 10% equity investment in Trilogy. He said that it was massive for not only the company, but also the district in general, as federal involvement brings validation to the importance of the project, creates stability, mitigates long-term risks, and shows how important these metals are to both the economy and national security.

Giardini was also asked about the key upcoming milestones for Trilogy, and he responded by saying that these include finalizing the road development plan, securing funding for the initial construction, and resuming project activities at the Ambler Mining District

When asked about the current and projected market dynamics, Giardini highlighted copper’s role as the backbone of energy infrastructure. He also added that cobalt and zinc are going to be crucial for batteries and storage technologies.

The conversation ends with Giardini stating he’s excited about the exploration potential of the district, and that he looks forward to seeing the road advance in a meaningful fashion.

About Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ)

Trilogy Metals Inc. is a mineral exploration and development company, with a focus on advancing critical mineral assets in Alaska. The company has the vision of responsibly developing the Ambler Mining District into a source of important minerals, while also delivering value to shareholders and local communities.

For more information, visit www.TrilogyMetals.com.

NOTE TO INVESTORS: The latest news and updates relating to TMQ are available in the company’s newsroom at ibn.fm/TMQ

• BluSky AI’s modular data centers will reflect the next generation of AI infrastructure, created to quickly meet the increasing demand for high-performance computing (“HPC”) and AI
• The firm’s SkyMod(TM) units will soon help deliver energy-efficient, scalable infrastructure capable of powering ML, AI, and data-intensive workloads
• By making efforts to solve the global need for computing power, the company is strategically positioning itself as a future leader in the AI revolution

While the tech industry has become fond of the use of large data centers, they now risk becoming outdated before being fully completed. More specifically, today’s evolving requirements of AI make it challenging for them to keep up. BluSky AI (OTC: BSAI) is reimagining the digital backbone of the AI era with an efficient, infrastructure-centered approach. With headquarters in Salt Lake City, Utah, the company is preparing to lead the future of the AI infrastructure through a new Neocloud network, to be hosted by its web of SkyMod(TM) data centers, called AI Factories. These technologies are proprietary to BSAI. The custom-built solution will support the increasing computational needs of machine learning, AI, and high-performance computing applications (ibn.fm/B3sRR).

With global AI ambitions severely impacted by limitations in access to compute power, the firm will soon provide flexible, fast, and lasting solutions. BluSky AI’s Neocloud, through the SkyMod series of prefabricated data centers, such as SkyMod(TM) XL and SkyMod(TM) One, will supply a ready-to-use network that will meet the compute-intensive needs of AI training and language-learning models. Every SkyMod is designed and built off-site, then deployed for use on either client facilities or powered land leased or owned by BlueSky AI, significantly reducing infrastructure and time-to-compute costs.

Within the past two quarters of 2025, BluSky AI has achieved major milestones to put them in a great position to leverage its network. The company announced six new sites spanning 130 acres and 85 MW of power across Utah, Colorado, Arizona and Nevada. In pursuit of a future NASDAQ listing, partnerships with Lilac to distribute a GPU marketplace partnership, and the re-engineering of a major chip manufacturer’s GPU to  fit for the SkyMod Factories, further expand BSAI’s ecosystem.

Building on its record of innovation, BluSky AI recently received an annual innovation achievement award from Utah Business in the manufacturing and development category. The firm’s leadership has broad experience in finance, telecoms, and technology. Dan Gay, the COO, has decades of operational leadership in the energy and technology fields, supporting the firm’s growing market partnership and expansion. CEO Trent D’Ambrosio is experienced in energy integration strategy and global telecom innovation. Julien Bedard, the CTO, comes with experience in cybersecurity, cloud architecture, and blockchain infrastructure.

With the rapid growth of AI adoption globally, the need for efficient, scalable compute power is on the rise. The global data center market is expected to reach $652 billion by 2030 from $347.6 billion in 2024, catalyzed by generative AI, machine learning, and Internet of Things adoption. BluSky AI’s GPU-centric design and rapid-deployment model give it strong leverage in the global market.

For more information, visit the company’s website at BluSkyAIDataCenters.com.

NOTE TO INVESTORS: The latest news and updates relating to BSAI are available in the company’s newsroom at https://ibn.fm/BSAI